Abstract

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar I disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Disclosed are methods of treating cavernous angiomas including cavernous angiomas with symptomatic hemorrhage with a 4-substituted piperidine derivative. Also disclosed are methods wherein administering the therapeutically effective amount of a 4-substituted piperidine derivative results in a Cmax of between about 3 ng/ml and about 60 ng/ml; and wherein a Tmax is achieved of between about 0.5 hours and about 1 hour of administering of a 4-substituted piperidine derivative.

IPC Classes  ?

• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed are methods of treating cavernous angiomas including cavernous angiomas with symptomatic hemorrhage with a 4-substituted piperidine derivative. Also disclosed are methods wherein administering the therapeutically effective amount of a 4-substituted piperidine derivative results in a Cmax of between about 3 ng/ml and about 60 ng/ml; and wherein a Tmax is achieved of between about 0.5 hours and about 1 hour of administering of a 4-substituted piperidine derivative.

IPC Classes  ?

• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present invention discloses a method for treating neurological diseases or disorders by administering an oral film containing a therapeutic compound with an average particle size D90 of less than about 160 microns. The oral film comprises a water-soluble polymer matrix, a water swellable polymer matrix, or a combination thereof, along with an additive selected from a group including sweeteners, flavors, flavor enhancers, fillers, plasticizers, dyes, pigments, permeation enhancers, buffers, preservatives, silicon dioxide, anti-tacking agents, or any combination thereof. This innovative approach provides a convenient and effective means of delivering a desired amount of the therapeutic compound for the treatment of neurological conditions.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/33 - Heterocyclic compounds

Abstract

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar I disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 8/67 - Vitamins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of the compositions for the treatment of seizure clusters increases the time to a second seizure and duration of the interseizure cluster interval.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Goods & Services

(1) Pharmaceutical preparations for the treatment of central nervous system disorders, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of epileptic seizures and anxiety; pharmaceutical preparations, namely, pain medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain; pharmaceutical preparations for the treatment of central nervous system disorders, namely, brain, movement, ocular motility and spinal cord diseases, pain, and conditions associated with pain sold in pre-filled medical apparatus and drug delivery devices; pharmaceutical preparations for the treatment of epileptic seizures and anxiety, sold in pre-filled medical apparatus and drug delivery devices (1) Pharmaceutical research and development services.

Abstract

The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof and methods of treatment of neurological conditions including cavernous angioma, cerebral aneurysm, stroke, subarachnoid hemorrhage, vasospasm after subarachnoid hemorrhage, traumatic brain injury, spinal cord injury, spinal cord injury stroke, seizures, hereditary hemorrhagic telangiectasis, cerebral arteriovascular malformations, sporadic cavernous angioma lesion, cerebral cavernous malformation, or combinations thereof, using the same.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 55/14 - Adipic acid
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof and methods of treatment of neurological conditions including cavernous angioma, cerebral aneurysm, stroke, subarachnoid hemorrhage, vasospasm after subarachnoid hemorrhage, traumatic brain injury, spinal cord injury, spinal cord injury stroke, seizures, hereditary hemorrhagic telangiectasis, cerebral arteriovascular malformations, sporadic cavernous angioma lesion, cerebral cavernous malformation, or combinations thereof, using the same.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

IPC Classes  ?

• A61K 31/33 - Heterocyclic compounds
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

Abstract

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/33 - Heterocyclic compounds
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Abstract

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose

Abstract

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/33 - Heterocyclic compounds
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Abstract

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/33 - Heterocyclic compounds
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of the compositions for the treatment of seizure clusters increases the time to a second seizure and duration of the interseizure cluster interval.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Goods & Services

Providing business information related to pharmaceutical products; business management services in the natures of providing computerized database and telephone communication management services, namely, aggregating and organizing electronic transmissions of voice mail, electronic mail and facsimile massages, and providing telephone answering services. Pharmacy benefit management services; financial administration of pharmacy reimbursement programs and services. Educational services and support related to pharmaceutical products, namely, telephonic instruction and courses, webinar instruction and courses, provided to health care providers, patients, and care partners in the field of pharmaceutical products, and digital or printable materials distributed therewith. Providing medical information accessible via a global computer network.

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Goods & Services

Pharmaceutical services, namely, proving business information related to pharmaceutical products; Business management services in the natures of providing computerized database and telephone communication management services, namely, aggregating and organizing electronic transmissions of voice mail, electronic mail and facsimile massages, and providing telephone answering services Pharmacy benefit management services; financial administration of pharmacy reimbursement programs and services Educational services and support related to pharmaceutical products, namely, telephonic instruction and courses, webinar instruction and courses, provided to health care providers, patients, and care partners in the field of pharmaceutical products, and digital or printable materials distributed therewith Providing medical information accessible via a global computer network

Goods & Services

pharmaceutical services, namely, proving business information related to pharmaceutical products; Business management services in the natures of providing computerized database and telephone communication management services, namely, aggregating and organizing electronic transmissions of voice mail, electronic mail and facsimile massages, and providing telephone answering services Pharmacy benefit management services; financial administration of pharmacy reimbursement programs and services Educational services and support related to pharmaceutical products, namely, telephonic instruction and courses, webinar instruction and courses, provided to health care providers, patients, and care partners in the field of pharmaceutical products, and digital or printable materials distributed therewith

Goods & Services

Educational services and support related to pharmaceutical products, namely, providing trainings in the field of pharmaceutical products and for the treatment of nervous system disorders providing medical information accessible via a global computer network

Goods & Services

Educational services and support related to pharmaceutical products, namely, providing trainings in the field of pharmaceutical products and for the treatment of nervous system disorders Providing medical information accessible via a global computer network

Goods & Services

Pharmaceutical services, namely, proving business information related to pharmaceutical products; Business management services in the natures of providing computerized database and telephone communication management services, namely, aggregating and organizing electronic transmissions of voice mail, electronic mail and facsimile massages, and providing telephone answering services Pharmacy benefit management services; financial administration of pharmacy reimbursement programs and services Educational services and support related to pharmaceutical products, namely, providing trainings in the field of pharmaceutical products and for the treatment of nervous system disorders Preparation and dispensing of prescriptions by pharmacists; providing medical information accessible via a global computer network; Pharmaceutical services, namely, proving pharmaceutical and medical advice in the field of pharmaceutical products

Goods & Services

Educational services and support related to pharmaceutical products, namely, providing trainings in the field of pharmaceutical products and for the treatment of nervous system disorders providing medical information accessible via a global computer network

Goods & Services

Educational services and support related to pharmaceutical products, namely providing trainings and classes in the field of pharmaceutical products and for the treatment of nervous system disorders sold in pre-filled medical apparatus and drug delivery devices providing medical information accessible via a global computer network

Goods & Services

Educational services and support related to pharmaceutical products, namely, providing trainings in the field of pharmaceutical products and for the treatment of nervous system disorders providing medical information accessible via a global computer network

Goods & Services

(1) Pharmaceutical preparations for the treatment of central nervous system disorders, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of epileptic seizures and anxiety; pharmaceutical preparations, namely, pain medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain; pharmaceutical preparations for the treatment of central nervous system disorders, namely, brain, movement, ocular motility and spinal cord diseases, pain, and conditions associated with pain sold in pre-filled medical apparatus and drug delivery devices; pharmaceutical preparations for the treatment of epileptic seizures and anxiety, sold in pre-filled medical apparatus and drug delivery devices (1) Pharmaceutical research and development services

Goods & Services

(1) Pharmaceutical preparations for the treatment of central nervous system disorders, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of epileptic seizures and anxiety; pharmaceutical preparations, namely, pain medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain; pharmaceutical preparations for the treatment of central nervous system disorders, namely, brain, movement, ocular motility and spinal cord diseases, pain, and conditions associated with pain sold in pre-filled medical apparatus and drug delivery devices; pharmaceutical preparations for the treatment of epileptic seizures and anxiety, sold in pre-filled medical apparatus and drug delivery devices, (1) Pharmaceutical research and development services.

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders; pharmaceutical preparations for the treatment of epileptic seizures and anxiety; pharmaceutical preparations, namely, pain medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain; pharmaceutical preparations for the treatment of nervous system disorders, pain, and conditions associated with pain sold in pre-filled medical apparatus and drug delivery devices; pharmaceutical preparations for the treatment of epileptic seizures and anxiety, sold in pre-filled medical apparatus and drug delivery devices. Pharmaceutical research and development services.

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders; pharmaceutical preparations for the treatment of epileptic seizures and anxiety; pharmaceutical preparations, namely, pain medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain; pharmaceutical preparations for the treatment of nervous system disorders, pain, and conditions associated with pain sold in pre-filled medical apparatus and drug delivery devices; pharmaceutical preparations for the treatment of epileptic seizures and anxiety, sold in pre-filled medical apparatus and drug delivery devices. Pharmaceutical research and development services.

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain and epileptic seizures, and anxiety; nasal spray preparations

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain and epileptic seizures, and anxiety; nasal spray preparations

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain and epileptic seizures, and anxiety; nasal spray preparations

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain and epileptic seizures, and anxiety; nasal spray preparations

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain and epileptic seizures, and anxiety; nasal spray preparations

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain and epileptic seizures, and anxiety; nasal spray preparations

Goods & Services

NASAL SPRAY PREPARATIONS

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain and epileptic seizures, and anxiety; pharmaceutical preparations for the treatment of nervous system disorders, epileptic seizures and anxiety, pain, and conditions associated with pain sold in pre-filled medical apparatus and drug delivery devices.

Goods & Services

(1) Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, and spinal cord diseases, and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain, for the relief of pain and for the treatment of epileptic seizures, and anxiety; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, and spinal cord diseases, epileptic seizures and anxiety, pain, and for the relief of pain sold in pre-filled medical apparatus and drug delivery devices

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders; pharmaceutical preparations for the treatment of epileptic seizures and anxiety; pharmaceutical preparations for the treatment of nervous system disorders sold in pre-filled medical apparatus and drug delivery devices;. pharmaceutical preparations for the treatment of epileptic seizures and anxiety, sold in pre-filled medical apparatus and drug delivery devices pharmaceutical research and development services

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders; pharmaceutical preparations for the treatment of epileptic seizures and anxiety; pharmaceutical preparations for the treatment of nervous system disorders sold in pre-filled medical apparatus and drug delivery devices;. pharmaceutical preparations for the treatment of epileptic seizures and anxiety, sold in pre-filled medical apparatus and drug delivery devices pharmaceutical research and development services

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders and epileptic seizures and anxiety; pharmaceutical preparations, namely, pain relief medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain and epileptic seizures, and anxiety; pharmaceutical preparations for the treatment of nervous system disorders, epileptic seizures and anxiety, pain, and conditions associated with pain sold in pre-filled medical apparatus and drug delivery devices

Goods & Services

pharmaceutical preparations for the treatment of nervous system disorders; pharmaceutical preparations, namely, pain medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain; pharmaceutical preparations for the treatment of nervous system disorders, pain, and conditions associated with pain sold in pre-filled medical apparatus and drug delivery devices pharmaceutical research and development services

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 9/08 - Solutions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Goods & Services

(1) Pharmaceutical preparations for the treatment of nervous system disorders, namely, epilepsy and seizure disorders, movement disorders, pain management, disorders associated with pain, metabolic disorders, neurodegenerative disorders, anxiety and depression disorders, panic disorders, schizophrenia, and bi-polar disorders; pharmaceutical preparations, namely, pain medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain; pharmaceutical devices, namely, medical apparatus and drug delivery devices for introducing pharmaceutical preparations into the human body. (1) Pharmaceutical research

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to pharmaceutical compositions comprising one or more
benzodiazepine drugs, one or more natural or synthetic tocopherols or
tocotrienols, and one or
more alcohols or glycols for nasal administration, methods for producing and
for using such
compositions.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 25/22 - Anxiolytics

Abstract

Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam

Goods & Services

Pharmaceutical preparations for the treatment of nervous system disorders; pharmaceutical preparations, namely, pain medication; pharmaceutical preparations for the treatment of pain and conditions associated with pain. Pharmaceutical devices, namely, medical apparatus and drug delivery devices for introducing pharmaceutical preparations into the human body. Pharmaceutical research.